Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
RARE•Ultragenyx entered into an agreement to sell a rare pediatric disease priority review voucher for $210 million.
1. Voucher sale agreement
Ultragenyx entered into an agreement to sell its rare pediatric disease priority review voucher for $210 million.
